Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure
スポンサーリンク
概要
- 論文の詳細を見る
Large-scale, placebo-controlled, randomized clinical trials have demonstrated that angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) reduce mortality and hospitalization in patients with heart failure (HF) caused by left ventricular systolic dysfunction (LVSD). However, it is unknown whether ACE inhibitors and ARBs have similar effects on the long-term outcomes in HF patients encountered in routine clinical practice. The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) enrolled HF patients hospitalized with worsening symptoms and they were followed during an average of 2.2 years. The outcome data were compared in patients with LVSD by echocardiography (ejection fraction <40%) according to the predischarge use of ACE inhibitors (n=356) or ARBs (n=372). The clinical characteristics were similar between patients with ACE inhibitor and ARB use except for higher prevalence of hypertensive etiology and diabetes mellitus. There was no significant difference between ACE inhibitor and ARB use in all cause death (adjusted hazard ratio [HR] 0.958, 95% CI 0.601-1.527, P=0.858) and rehospitalization (adjusted HR 0.964, 95% CI 0.683-1.362, P=0.836). The effects of ACE inhibitor and ARB use on the outcomes were generally consistent across all clinically relevant subgroups examined, including age, sex, etiology, EF, hypertension, diabetes mellitus, and β-blocker use. Discharge use of ARBs provided comparable effects with ACE inhibitors on outcomes in patients hospitalized for HF. These findings provide further support for guideline recommendations that ARBs can be used in patients with HF and LVSD as an alternative of ACE inhibitors.
- 2010-03-01
著者
-
Takeshita Akira
Saiseikai Futsukaichi Hospital
-
Tsutsui Hiroyuki
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Hokkaido University
-
Yoshida H
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Yokoshiki Hisashi
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
TSUCHIHASHI MAKAYA
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
FURUMOTO Tomoo
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
KINUGAWA Shintaro
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
HAMAGUCHI Sanae
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
GOTO Kazutomo
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
GOTO Daisuke
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
YAMADA Satoshi
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
TAKESHITA Akira
Futsukaichi Saiseikai Hospital
-
Kinugawa Shintaro
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Kinugawa Shintaro
Department Of Cardiovascular Medicine Hokkaido University
-
Goto Daisuke
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Gotoh Kazutomo
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Takeshita A
Futsukaichi Saiseikai Hospital
-
Hamaguchi Sanae
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Takeshita Akira
国立国際医療センター研究所 医療情報解析研究部
-
Tsuchihashi Miyuki
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Togashi Hiroko
筑波大学 臨床医学系循環器内科
-
Togashi Hiroko
北海道大学 医学研究科 薬理
-
Togashi Hiroko
北海道大学
-
Tsuchihashi-Makaya Miyuki
Department of Gene Diagnostics and Therapeutics, Research Institute, International Medical Center of
-
Tsutsui Hiroyuki
Department Of Cardiovascular Medicine
-
Goto Kazutomo
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Yamada Satoshi
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Furumoto Tomoo
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Togashi Hiroko
Department Of Pharmacology Hokkaido University Graduate School Of Medicine
-
Makaya Miyuki
Kyushu University Graduate School Of Medical Sciences
-
Togashi Hiroko
Safety Research Institute For Chemical Compounds
-
Tsutsui Hiroyuki
Department Of Cardiovasucular Medicine Graduate School Of Medical Sciences Kyushu University
-
Togashi Hiroko
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Makaya Miyuki
Department Of Cardiovasucular Medicine Graduate School Of Medical Sciences Kyushu University
-
Yokoi Hisataka
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Togashi Hiroko
1st Dept. Of Pharmacol. Hokkaido Univ. Sch. Of Med.
-
Tsutsui Hiroyuki
Department Of Cardiovascular Medicine Hokkaido University Hospital
-
Takeshita Akira
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Tsuchihashi Makaya
Department Of Cardiovascular Medicine Hokkaido University Graduate School Of Medicine
-
Makaya Miyuki
International Medical Center Of Japan
-
Tanaka Atsushi
Department Of Cardiovascular Medicine Kyushu University
-
Tsuchihashi Makaya
Department Of Clinical Research And Informatics Research Institute International Medical Center Of J
-
Tsuchihashi Makaya
Department Of Clinical Research And Informatics Research Institute International Medical Center Of J
-
Togashi Hiroko
Department Of Neuropharmacology Hokkaido University Graduate School Of Medicine
-
Tsuchihashi Makaya
Department Of Clinical Research And Informatics Research Institute International Medical Center Of J
-
Tsuchihashi-Makaya Miyuki
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine
-
TSUTSUI Hiroyuki
Department of Cardiology, Iizuka Hospital
関連論文
- Body Mass Index can Similarly Predict the Presence of Multiple Cardiovascular Risk Factors in Middle-aged Japanese Subjects as Waist Circumference
- Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure
- 7 Anxiety and Poor Social Support are Independently Associated with Adverse Outcomes in Patients with Mild Heart Failure(Is Stress a Risk of Cardiovascular Disease?,Symposium 22 (SY-22) (I),The 73rd Annual Scientific Meeting of The Japanese Circulation So
- 7 Anxiety and Poor Social Support are Independently Associated with Adverse Outcomes in Patients with Mild Heart Failure(Is Stress a Risk of Cardiovascular Disease?,Symposium 22 (SY-22) (I),The 73rd Annual Scientific Meeting of The Japanese Circulation So
- Which is most Beneficial for Preserving Cardiac Function and Coronary Microvasculaturein DCM, ACE-I, ARB or Two in Combination? (Cardiac Hypertrophy/Cardiomyopathy 2 (M), The 69th Annual Scientific Meeting of the Japanese Circulation Society)
- Eplerenone Prevents Cardiac Fibrosis through the Inhibition of OPN Expression (Cardiac Hypertrophy, Basic (M), The 69th Annual Scientific Meeting of the Japanese Circulation Society)
- Osteopontin is Essential for Angiotensin II-Induced Cardiac Fibrosis(Heart Failure, Basic 2 (M), The 69th Annual Scientific Meeting of the Japanese Circulation Society)
- Angiotensin II Receptor Blocker, Valsartan, Increases Myocardial Blood Volume and Regresses Hypertrophy in Hypertensive Patients
- Effects of Atrial Fibrillation on Long-Term Outcomes in Patients Hospitalized for Heart Failure in Japan : A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)
- Anemia is an Independent Predictor of Long-Term Adverse Outcomes in Patients Hospitalized With Heart Failure in Japan : A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)